Tags

Type your tag names separated by a space and hit enter

Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement.
Reprod Med Biol 2019; 18(3):290-295RM

Abstract

Purpose

The clinical utility of chlormadinone acetate tablets (Lutoral™), an orally active progestin which has been available since June 2007, was compared to an in-house vaginal suppository formulation of progesterone used between 2006 and 2007 for assisted reproductive technology (ART).

Methods

We retrospectively evaluated the efficacy and safety of chlormadinone acetate by comparing the pregnancy rates and the incidences of birth defects and hypospadias in frozen-thawed embryo transfer cycles using the in-house vaginal progesterone and those using chlormadinone acetate for luteal phase support.

Results

The pregnancy rates in the frozen-thawed embryo transfer cycles were 31.2% (259/831) with vaginal progesterone for luteal phase support and 31.6% (4228/13 381) with chlormadinone acetate (no significant difference). In the cycles resulting in live birth following administration of chlormadinone acetate between July 2007 and December 2015, the incidence of birth defects was 2.8% (80/2893), and the incidence of hypospadias was 0.03% (1/2893).

Conclusions

These results indicate that the pregnancy rate following frozen-thawed embryo transfer using chlormadinone acetate for luteal phase support was comparable with that using vaginal progesterone, with no increased risk of birth defects, including hypospadias, which has been a concern following the use of progestins.

Authors+Show Affiliations

Asada Ladies Clinic Nagoya Japan. Asada Institute for Reproductive Medicine Kasugai Japan.Asada Ladies Clinic Nagoya Japan.Asada Ladies Clinic Nagoya Japan.Asada Ladies Clinic Nagoya Japan.Asada Ladies Clinic Nagoya Japan.Asada Ladies Clinic Nagoya Japan. Asada Institute for Reproductive Medicine Kasugai Japan.Asada Ladies Clinic Nagoya Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31312109

Citation

Asada, Yoshimasa, et al. "Clinical Utility of Chlormadinone Acetate (Lutoral™) in Frozen-thawed Embryo Transfer With Hormone Replacement." Reproductive Medicine and Biology, vol. 18, no. 3, 2019, pp. 290-295.
Asada Y, Hashiba Y, Hattori Y, et al. Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement. Reprod Med Biol. 2019;18(3):290-295.
Asada, Y., Hashiba, Y., Hattori, Y., Inoue, D., Ito, R., Fukunaga, N., & Sonohara, M. (2019). Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement. Reproductive Medicine and Biology, 18(3), pp. 290-295. doi:10.1002/rmb2.12274.
Asada Y, et al. Clinical Utility of Chlormadinone Acetate (Lutoral™) in Frozen-thawed Embryo Transfer With Hormone Replacement. Reprod Med Biol. 2019;18(3):290-295. PubMed PMID: 31312109.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical utility of chlormadinone acetate (Lutoral™) in frozen-thawed embryo transfer with hormone replacement. AU - Asada,Yoshimasa, AU - Hashiba,Yoshiki, AU - Hattori,Yukio, AU - Inoue,Daichi, AU - Ito,Rie, AU - Fukunaga,Noritaka, AU - Sonohara,Megumi, Y1 - 2019/05/09/ PY - 2018/10/02/received PY - 2019/03/27/revised PY - 2019/04/22/accepted PY - 2019/7/18/entrez PY - 2019/7/18/pubmed PY - 2019/7/18/medline KW - assisted reproductive technology KW - endometrial preparation KW - frozen‐thawed embryo transfer KW - luteal phase support KW - orally active progestin SP - 290 EP - 295 JF - Reproductive medicine and biology JO - Reprod. Med. Biol. VL - 18 IS - 3 N2 - Purpose: The clinical utility of chlormadinone acetate tablets (Lutoral™), an orally active progestin which has been available since June 2007, was compared to an in-house vaginal suppository formulation of progesterone used between 2006 and 2007 for assisted reproductive technology (ART). Methods: We retrospectively evaluated the efficacy and safety of chlormadinone acetate by comparing the pregnancy rates and the incidences of birth defects and hypospadias in frozen-thawed embryo transfer cycles using the in-house vaginal progesterone and those using chlormadinone acetate for luteal phase support. Results: The pregnancy rates in the frozen-thawed embryo transfer cycles were 31.2% (259/831) with vaginal progesterone for luteal phase support and 31.6% (4228/13 381) with chlormadinone acetate (no significant difference). In the cycles resulting in live birth following administration of chlormadinone acetate between July 2007 and December 2015, the incidence of birth defects was 2.8% (80/2893), and the incidence of hypospadias was 0.03% (1/2893). Conclusions: These results indicate that the pregnancy rate following frozen-thawed embryo transfer using chlormadinone acetate for luteal phase support was comparable with that using vaginal progesterone, with no increased risk of birth defects, including hypospadias, which has been a concern following the use of progestins. SN - 1445-5781 UR - https://www.unboundmedicine.com/medline/citation/31312109/Clinical_utility_of_chlormadinone_acetate_(Lutoral™)_in_frozen-thawed_embryo_transfer_with_hormone_replacement L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/31312109/ DB - PRIME DP - Unbound Medicine ER -